

Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2019/2020 influenza season

as of March 30, 2020, June 30, 2020

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
Resistant (%)	1 ^a (0.15%)	22 ^b (1.3%)	22 ^b (1.3%)	0	0	10 (100%)	0	0	0	0	0	5 (100%)	0	0	0	0	0
Number of viruses tested	680	1,657	1,657	231	231	10	42	32	32	32	32	5	20	37	37	37	37
Number of viruses reported	4,369						110						420				

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.

^a Patients without treatment 1

^b Patients without treatment 14